A case of Rowell syndrome with excellent improvement following anifrolumab

Abstract

Rowell syndrome (RS), a rare and severe variant of cutaneous lupus erythematosus (CLE), is described as a cutaneous eruption resembling erythema multiforme (EM) with features of systemic lupus erythematous (SLE) and characteristic serology.1 Therapeutic options for RS include those used to treat SLE, such as corticosteroids, hydroxychloroquine (HCQ), immunosuppression, and biologic therapies.2 In 2021, anifrolumab, a monoclonal antibody that selectively binds and inhibits the type 1 interferon- α receptor 1 (IFNAR1), received Food and Drug Administration-approval for the treatment of SLE.

Topics & Concepts